+55%

est. 2Y upside i

HealthcareSeries C

Rank

#927

Sector

Biotechnology

Est. Liquidity

~2Y

Data Quality

Data: Low

Cellworks offers moderate upside potential but high risk due to stale valuation, high capital intensity, and severe preference overhang.

Last updated: July 19, 2026

Bull (20%)+118%

If Cellworks achieves an IPO window or category leadership, multiple holds at 6x. Projected revenue $47.5M yields $285M exit, 137.5% pre-dilution, net 117.5%.

Base (55%)+58%

Multiple converges to public comp median of 4.5x on $47.5M revenue, exit $213.75M, 78.1% pre-dilution, net 58.1%.

Bear (25%)-1%

Multiple compresses to 3x from competition or funding issues, exit $142.5M, 18.75% pre-dilution, net -1.25%. Preference stack at 45% of valuation but exit above funding so common still recovers.

Est. time to liquidity~2.0 years

Preference Stack Risk

severe

Funding Intensity

182%

Total funding of $54.3M represents 45% of estimated entry valuation of $120M, creating a significant overhang for common stock.

Dilution Risk

high

Given no recent funding and high burn, a dilutive raise within 24 months is likely, estimated at 20% dilution.

Secondary Liquidity

none

No secondary market activity detected.

Questions to Ask at the Interview

Strategic questions based on Cellworks's data — designed to show you've done your homework.

  • 1

    “How does Cellworks plan to achieve profitability given high capital intensity?”

  • 2

    “What is the current revenue growth rate and what are the key drivers?”

  • 3

    “With the last funding round over 3 years ago, what is the company's cash runway and plans for future fundraising?”

Community

Valuation Sentiment

Our model estimates +55% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.